Zacks Investment Research announced China Biologic Products Inc (NASDAQ:CBPO), boosting its stock price target to $138.00 today
- Updated: October 10, 2016
In a report issued 10/10/2016 Zacks Investment Research upped the price target of China Biologic Products Inc (NASDAQ:CBPO) to $138.00 stating a potential upside of 0.12%.
On 7/09/2015, Bank of America released a statement about China Biologic Products Inc (NASDAQ:CBPO) upped the target price from $0.00 to $135.00 that suggested an upside of 0%.
Having a price of $123.18, China Biologic Products Inc (NASDAQ:CBPO) traded 0.38% higher on the day. With the last stock price up 5.06% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CBPO has recorded a 50-day average of $119.27 and a two hundred day average of $117.24. Trade Volume was down over the average, with 76,299 shares of CBPO changing hands under the typical 218,494
Recent Performance Chart
China Biologic Products Inc has 52 week low of $95.70 and a 52 week high of $144.29 with a P/E ratio of 35.52 and has a market cap of $0.
About China Biologic Products Inc (NASDAQ:CBPO)
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories. Its principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through approximately two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xi'an Huitian Blood Products Co., Ltd., a plasma products company. Its products also include Human rabies immunoglobulin, Human tetanus immunoglobulin, Placenta polypeptide, Factor VIII and Human prothrombin complex concentrate.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.